Arcutis Biotherapeutics Inc. (ARQT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Arcutis Biotherapeutics Inc. (ARQT) advanced +1.65% to $31.97 as options desks priced 61% call premium vs. 39% put protection around the $31 max-pain magnet. Solid 90% profit margin (-3% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WESTLAKE VILLAGE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, to
Arcutis (ARQT) pairs top technical strength with high growth momentum and a bull flag setup, though resistance and slowing sales are key risks.
WESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, t
Arcutis Biotherapeutics (ARQT) clears all eight of Louis Navellier’s growth rules, showing strong revenue, earnings, and cash flow momentum.
WESTLAKE VILLAGE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, t
ARQT stock looks undervalued on forward multiples, with strong margins, a solid balance sheet and rapid earnings growth backing its value case.
Arcutis Biotherapeutics (NASDAQ:ARQT) saw its share price jump by 10.65 percent to close at $31.89 apiece after earning a bullish outlook and a double-digit price target hike from an analyst. In its market note, investme
Arcutis Biotherapeutics reported past conference data on its ZORYVE portfolio, including Phase 2 INTEGUMENT-INFANT results in atopic dermatitis and multiple analyses across creams and foams for plaque psoriasis and sebor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +91.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARQT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARQT. Explore sector supply chains on /butterfly.
Why ARQT Stock advanced +1.65% Today — RQD Quant Desk Flash. Solid 90% profit margin (-3% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.